Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887341 | 1.00 | HDAC1 (0.69) | HDAC1HDAC6CXCR4GRIN2BKDM4E | |
| SCHEMBL13909820 | 0.94 | HDAC1 (0.76) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL21055028 | 0.88 | HDAC1 (0.68) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL4065807 | 0.88 | HDAC1 (0.68) | HDAC1HDAC6CXCR4GRIN2BKDM4E | |
| SCHEMBL5656928 | 0.88 | HDAC1 (0.61) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL14025462 | 0.87 | HDAC1 (0.60) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL4066161 | 0.86 | HDAC1 (0.63) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL30379489 | 0.86 | HDAC1 (0.61) | HDAC1HDAC6CXCR4CYP2D6 | |
| Bromide SCHEMBL5140296 | 0.85 | HDAC1 (0.62) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL29823139 | 0.85 | HDAC1 (0.62) | HDAC1HDAC6CXCR4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462711-B | Bidentate nitrogen-manganese complex, preparation method thereof, catalyst composition and application | 河北农业大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-116462711-A | Bidentate nitrogen-manganese complex, preparation method thereof, catalyst composition and application | 河北农业大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178271-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100003224-A1 | Combination Therapy | GENZYME CORPORATION (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1784185-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| WO-2008019371-A1 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017025-A2 | COMBINATION THERAPY | GENZYME CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| EP-1784185-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007022523-A2 | METHODS TO ENHANCE CHEMOTHERAPY | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | disclosed |
| WO-2006028896-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006020891-A2 | CHEMOKINE COMBINATIONS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043012-A1 | Methods to enhance chemotherapy | CXCR4, MCL1, CXCL12 | HDAC1 1036/4885HDAC6 1262/4885CXCR4 1/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885CXCR4 9/4885 |
| US-20100178271-A1 | Combination Therapy | CXCL12, CSF3R, CXCR4 | HDAC1 1868/4885HDAC6 1232/4885CXCR4 3/4885 |
| US-20100003224-A1 | Combination Therapy | CXCL12, CXCR4, SDF4 | HDAC1 1195/4885HDAC6 926/4885CXCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.